European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - drotrecogin alfa (activated) - sepsis; multiple organ failure - antithrombotic agents - xigris is indicated for the treatment of adult patients with severe sepsis with multiple organ failure when added to best standard care. the use of xigris should be considered mainly in situations when therapy can be started within 24 hours after the onset of organ failure (for further information see section 5.1).

Canada - English - Health Canada

eli lilly canada inc - drotrecogin alfa (activated) - powder for solution - 5mg - drotrecogin alfa (activated) 5mg - other miscellaneous therapeutic agents

Canada - English - Health Canada

eli lilly canada inc - drotrecogin alfa (activated) - powder for solution - 20mg - drotrecogin alfa (activated) 20mg - other miscellaneous therapeutic agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - drotrecogin alfa - powder for solution for infusion - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - drotrecogin alfa - powder for solution for infusion - 20mg